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Abstract
Background: Randomised controlled trials (RCTs) represent the gold standard methodological
design to evaluate the effectiveness of an intervention in humans but they are subject to bias,
including study publication bias and outcome reporting bias. National and international
organisations and charities give recommendations for good research practice in relation to RCTs
but to date no review of these guidelines has been undertaken with respect to reporting bias.
Methods:  National and international organisations and UK based charities listed on the
Association for Medical Research Charities website were contacted in 2007; they were considered
eligible for this review if they funded RCTs. Guidelines were obtained and assessed in relation to
what was written about trial registration, protocol adherence and trial publication. It was also
noted whether any monitoring against these guidelines was undertaken. This information was
necessary to discover how much guidance researchers are given on the publication of results, in
order to prevent study publication bias and outcome reporting bias.
Results: Seventeen organisations and 56 charities were eligible of 140 surveyed for this review,
although there was no response from 12. Trial registration, protocol adherence, trial publication
and monitoring against the guidelines were often explicitly discussed or implicitly referred too.
However, only eleven of these organisations or charities mentioned the publication of negative as
well as positive outcomes and just three of the organisations specifically stated that the statistical
analysis plan should be strictly adhered to and all changes should be reported.
Conclusion: Our review indicates that there is a need to provide more detailed guidance for
those conducting and reporting clinical trials to help prevent the selective reporting of results.
Statements found in the guidelines generally refer to publication bias rather than outcome
reporting bias. Current guidelines need to be updated and include the statement that all primary
and secondary outcomes prespecified in the protocol should be fully reported and should not be
selected for inclusion in the final report based on their results.
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Introduction
Randomised controlled trials (RCTs) are planned experi-
ments, involving the random assignment of patients to
interventions, and are seen as the gold standard of meth-
odological designs to evaluate the effectiveness of a treat-
ment in medical research in humans [1].
However, empirical research consistently suggests that
published work is more likely to be statistically significant
(P < 0.05) than unpublished research, and significant
results have a higher probability of being published than
non-significant outcomes [2]. Evidence also suggests that
published research without statistically significant results
takes much longer to achieve publication than its statisti-
cally significant counterparts, further biasing evidence
over time [3-5]. Such "study publication bias" is well rec-
ognised as a potential threat to the validity of any infer-
ence made as a result of a review of the literature [6].
Outcome reporting bias (ORB) has been defined as the
selection on the basis of the results of a subset of the orig-
inal variables recorded for inclusion in publication of tri-
als [7]. Recent work [8-14] provides direct empirical
evidence for the existence of outcome reporting bias.
Chan et al [11] compared publications with protocols for
102 RCTs and found that statistically significant outcomes
had a higher odds of being fully reported compared to
non-significant outcomes for data both on efficacy
(pooled odds ratio 2.4, 95% confidence interval 1.4 to
4.0) and safety (4.7, 1.8 to 12). Further, 62% of trials had
at least one primary outcome that was changed, intro-
duced, or omitted. A second study of 48 trials funded by
the Canadian Institutes of Health Research found similar
results [10] as have more recent studies [12,13]. Other
researchers have also concluded the problem to be major,
and deserving of substantially more attention than it cur-
rently receives [15].
The registration of RCTs before initiation, on clinical trial
registries [16], is one step forward in trying to prevent
reporting biases as there is documentation that the trials
exist, so that reviewers are able to search these registries in
order to locate unpublished trials to include in a system-
atic review.
Organisations that fund clinical trials often issue research
guidelines to aid trialists in the conduct of their study. A
review of these guidelines has been conducted to discover
how much guidance research funders give concerning the
publication of results. That review is the focus of this
report.
Particular international guidelines [ICH Harmonised Tri-
partite Guideline for Good Clinical Practice (E6) [17], The
EU Clinical Trials Directive [18], The Declaration of Hel-
sinki [19] and the CONSORT Statement [20] were fre-
quently referred to by funders of clinical trials and are thus
briefly described first in terms of their coverage of publi-
cation issues.
The International Conference on Harmonisation Good
Clinical Practice (ICH GCP) guideline came into effect in
1997 and "is an international ethical and scientific quality
standard for designing, conducting, recording, and report-
ing trials that involve the participation of human subjects
[17]." It was introduced to provide a unified standard for
the United States, EU, and Japan to facilitate acceptance of
clinical data by the respective regulatory authorities [21].
The ICH GCP guidelines do not mention trial registration
but do state that "All important deviations related to study
inclusion or exclusion criteria, conduct of the trial, patient
management or patient assessment should be described.
Adherence to the study protocol is essential. If modifica-
tion of the protocol becomes necessary a clear description
of the rationale for the modification should be provided
in a protocol amendment." This relates to the issue of
ORB because if outcomes are changed from those stated in
the protocol for valid reasons, this should be documented
before the write up of any trial reports so that it is obvious
that results have not been selectively reported based on
their results.
Regarding the primary outcome of a trial, the ICH GCP
guidelines state "The primary measurements and end-
points used to determine efficacy should be clearly speci-
fied. There should generally only be one primary variable.
The primary variable should be specified in the protocol,
along with the rationale for its selection. Redefinition of
the primary variable after unblinding will almost always
be unacceptable, since the biases this introduces are diffi-
cult to assess." The guidelines also state that "The results
of a clinical trial should be analysed in accordance with
the plan prospectively stated in the protocol and all devi-
ations from the plan should be indicated in the study
report. In the statistical section of the clinical study report
the statistical methodology should be clearly described
including when in the clinical trial process methodology
decisions were made." This indicates that the primary out-
come should usually not change between protocol and
publication of the trial report; if there is a change, it
should be documented and explained in the trial report.
The Declaration of Helsinki [19] was first adopted in 1964
and has since been revised five times by the World Medi-
cal Association, most recently in 2000, although clarifica-
tions have been added since (2002 and 2004).
Publication is discussed, stating that "Both authors and
publishers have ethical obligations. In publication of the
results of research, the investigators are obliged to pre-
serve the accuracy of the results. Negative as well as posi-Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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tive results should be published or otherwise publicly
available. Sources of funding, institutional affiliations
and any possible conflicts of interest should be declared
in the publication. Reports of experimentation not in
accordance with the principles laid down in this Declara-
tion should not be accepted for publication."
The CONSORT (Consolidated Standards of Reporting Tri-
als) Statement is intended to improve the reporting of a
randomised controlled trial [20]. It comprises a checklist
of 22 essential items to be reported and a flow diagram.
CONSORT includes a recommendation that the methods
section should include information on 'clearly defined
primary and secondary outcome measures and, when
applicable, any methods used to enhance the quality of
measurements'. The results section of CONSORT states
'For each primary and secondary outcome, a summary of
results for each group, and the estimated effect size and its
precision (e.g. 95% confidence interval)' should be
reported.
The EU Clinical Trials Directive 2001 (updated in 2005)
[18] was transposed into UK law through The Medicines
for Human Use (Clinical Trials) Regulations 2004 [22].
The aims of this Directive was to "protect the rights, safety
and well being of trial participants, to simplify and har-
monise the administrative provisions governing clinical
trials and to establish a transparent procedure that would
harmonise trial conduct in the EU and ensure the credibil-
ity of results." The Directive refers to the Declaration of
Helsinki and discusses the monitoring of trials and proto-
col adherence, stating that "after the commencement of
the clinical trial, the sponsor may make amendments to
the protocol. If those amendments are substantial and are
likely to have an impact on the safety of the trial subjects
or to change the interpretation of the scientific documents
in support of the conduct of the trial, or if they are other-
wise significant, the sponsor shall notify the competent
authorities of the Member State or Member States con-
cerned of the reasons for, and content of, these amend-
ments and shall inform the ethics committee or
committees concerned." This relates to the issue of ORB
due to the reasons stated above regarding protocol devia-
tions/amendments for the ICH GCP guidelines.
Methods
A survey of major research organisations and UK charities
(see Additional file 1, Appendix 1), using the same list as
The DAMOCLES project [23], was undertaken to examine
whether existing guidelines for research conduct refer to
issues related to reporting biases. UK based charities listed
on the Association for Medical Research Charities website
were contacted (see Additional file 1, Appendix 1).
National and international organisations were selected if
they funded research in the United Kingdom, since it was
felt important to obtain information from different fund-
ing sources and from different international geographical
locations. Research organisations were eligible if they
fund clinical trials.
Ascertainment
Search terms that were used when searching for guidelines
on the websites of major research organisations included;
"research practice", "research conduct", "registration of
trial and outcomes", "protocol adherence", "protocol
amendments", "reporting results", "publication" and
"researchers' handbook". When guidelines were identified
they were obtained and reviewed. The organisations were
also contacted by email to ensure all of the information
available was obtained.
For some organisations no document could be located
through their website. In these cases we requested infor-
mation by a shortened version of the questionnaire (see
Additional file 1, Appendix 2) on issues related to out-
come reporting. This questionnaire was sent via email if
possible, or by post otherwise.
KD extracted information from all guidelines that were
obtained, and PW carried out a random check that all rel-
evant information had been extracted. The information
relating to each organisation or charity was then sent to
the contact individual for review so that we could ensure
that all information was correct and if there was anything
else to be added.
We also contacted all 108 charities (see Additional file 1,
Appendix 1) listed on the Association for Medical
Research Charities website http://www.amrc.org.uk to
find out if they fund clinical trials, and if so, what was the
maximum grant available. A questionnaire (see Addi-
tional file 1, Appendix 2) was then sent to those charities
that funded RCTs. The search of the AMRC website was
done more than once.
The final search of the AMRC website in September 2007
indicated that 7 more charities had been added, while 2
from the original list that we contacted had been removed
(National Eczema Society and Tyneside Leukaemia
Research Association) and 2 charities have been incorpo-
rated into Epilepsy Research UK (Epilepsy Research Foun-
dation and Fund for Epilepsy).
Data from all organisations and charities were entered
into a Microsoft Access database with data entry screens in
the form of the original questionnaire (see Additional file
1, Appendix 3). The questionnaire in appendix 2 (see
Additional file 1) was used as a means of contacting the
funding agency and requesting a copy of their guidelinesTrials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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and the questionnaire in appendix 3 (see Additional file
1) was used when reading through guidelines.
Under "protocol adherence/amendment" we considered
whether there was any reference in the guidelines to these
issues (i.e. do the guidelines state that the protocol should
be adhered to? Do the guidelines give any information on
what to do if there are changes to the protocol?) This
would cover the issue of ORB as any legitimate changes to
changes of outcomes should be reported. Under "trial
publication" we sought any statement referring to publi-
cation (i.e. if it should be published, where it should be
published, when it should be published, what should be
included in the publication etc.). For "monitoring against
guidelines" we looked for a reference to monitoring for
adherence to the published guidelines.
Analysis
Descriptive results from the questionnaire are presented.
Data are tabulated and excerpts found in the guidelines
relating to the issue of outcome reporting are used to sup-
port statements made.
Results
Organisations and charities
Twenty five organisations were contacted of which 17
were eligible. There were 115 charities listed on the AMRC
website (108 originally listed charities including the 2
charities which were later removed from the website plus
7 newly added charities) of which 56 were eligible (Table
1). Eight organisations and 48 charities were not eligible
as they did not fund clinical trials. There was no reply
from the remaining 11 charities.
Search for guidelines
Websites for all 73 eligible organisations and charities
were accessed but the success in searching for guidelines
was mixed. Some were relatively easy to find and well
directed by the organisation (e.g. Medical Research Coun-
cil), while others proved more difficult to find. The web-
sites for Health Technology Assessment (HTA) and
National Institute of Health (NIH), for example, provided
a lot of information making it difficult to find the required
guidelines.
Fifty two charities and 14 organisations had guidelines for
RCTs or sent the terms and conditions of a grant. There
was limited contact with one charity and two organisa-
tions (and there was no relevant information on their
websites), one charity and one organisation said they had
no guidelines and two charities would not send their
guidelines/terms and conditions due to confidentiality.
Eight of the charities and three of the organisations did
not respond when we asked them to check the informa-
tion we had extracted.
The guidelines were requested as per Appendix 2 (see
Additional file 1). In some cases we were sent the terms
and conditions of the grant and when we followed up to
request research guidelines nothing more was available.
The terms and conditions were mostly concerned with the
legalities of the funding and did not contain information
that we were looking for.
As the websites were searched several times and all organ-
isations and charities were also contacted on several occa-
sions, the information regarding how many guidelines
were identified on the websites is not available. Even if
information was found on the website, each charity and
organisation was contacted to enquire whether there was
any other information available. Most of the information
was obtained through contact with the organisation/char-
ity. Even if the questionnaire was returned the question
on how the guidelines were issued to the researcher was
often not answered; only 30 (41%) organisations/chari-
ties stated that the guidelines were sent by post/email (11
(37%)), supplied with the grant application (11 (37%))
or researchers were referred to their website (8 (26%)).
Guidelines
Table 1 summarises the responses from the organisations
and charities that fund RCTs. By explicit reference it is
meant that the charities/organisations guidelines referred
to one of the guideline domains (trial registration, proto-
col adherence, publication, or monitoring) within their
guidelines. By implicit it is meant that the charities/organ-
isations guidelines referred to other guidelines such as
CONSORT, ICH E6 guidelines etc which referred to the
guideline domains.
Of the guidelines issued by the organisations and chari-
ties, 19 (26%) stated explicitly that a trial should be regis-
tered although a further 29 (40%) referred to trial
registration implicitly through their reference to other
guidelines such as AMRC, MRC or the Department of
Health Research Governance Framework. Protocol adher-
ence and protocol amendment were discussed explicitly
in 32 (44%) and implicitly in 26 (36%) of the guidelines
although not specifically in relation to outcomes; they
state only that the protocol should be followed, all major
amendments need ethics committee approval (or similar)
and minor amendments need to be recorded. Publication
was explicitly referred to in 49 (67%) and implicitly in 14
(19%) of the guidelines/terms and conditions. They state
that trials should be monitored with regards to the guide-
lines (47 (64%) explicitly and 12 (16%) implicitly). Pub-
lication of negative and positive findings were explicitly
referred to in 11 (15%) and implicitly in 27 (37%) of the
guidelines/terms and conditions. The large majority refer
to other guidelines (Table 1).Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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Table 1: Summary of response from organisations and charities
Action Number of organisations 
(percentage)
Number of charities (percentage) Total (percentage)
Contacted 25 115 140
Eligibility
Eligible 17 (68%) 56 (49%) 73 (52%)
Not eligible 4 (16%) 48 (42%) 52 (37%)
No reply 0 (0%) 11 (9%) 11 (8%)
Issue guidelines but do not fund RCTs 4 (16%) 0 (0%) 4 (3%)
Guidelines (n = 73)
Guidelines/terms and conditions 
received
14 (82%) 52 (93%) 66 (90%)
Limited contact 2 (12%) 1 (2%) 3 (4%)
No guidelines 1 (6%) 1 (2%) 2 (3%)
Could not send due to confidentiality 0 (0%) 2 (3%) 2 (3%)
Research funder not checked table of 
information
3 (18%) 8 (14%) 11 (15%)
Not referred to other guidelines 3 (18%) 14 (25%) 17 (23%)
Referred to other guidelines:1 14 (82%) 42 (75%) 56 (77%)
Association of Medical Research 
Charities
0 (0%) 18 (43%) 18 (32%)
Department of Health Research 
Governance Framework (England)
3 (21%) 15 (36%) 18 (32%)
Medical Research Council 5 (36%) 13 (31%) 18 (32%)
International Conference on 
Harmonisation (ICH)
10 (71%) 4 (10%) 14 (25%)
Medicines for Human use 6 (43%) 8 (19%) 14 (25%)
Institution 0 (0%) 11 (26%) 11 (20%)
Declaration of Helsinki 7 (50%) 2 (5%) 9 (16%)
CONSORT 6 (43%) 0 (0%) 6 (11%)Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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Association of Medical Research Charity guidelines
The AMRC guidelines on good research practice [24]
refers to the Department of Health Research Governance
Framework, MRC guidelines for good clinical practice,
and Wellcome Trust guidelines and state that the institu-
tion should implement good research practice. The guide-
lines encourage publication in peer reviewed journals and
dissemination of research.
Statements specific to outcomes, ORB or publication bias
Table 2 includes statements found in the guidelines that
are specific to outcomes, ORB or publication bias. Eleven
(15%) of the 73 organisations or charities and non-fund-
ing organisations mention the importance of publication
of negative as well as positive findings. Three (4%) of the
organisations specifically state that the statistical analysis
plan should be strictly adhered to and all changes should
Charity specific 0 (0%) 4 (10%) 4 (7%)
National regulations and guidelines 1 (7%) 3 (7%) 4 (7%)
Legal 0 (0%) 4 (10%) 4 (7%)
Wellcome Trust 0 (0%) 3 (7%) 3 (5%)
Reference in guidelines/through 
contact (n = 73) to:
Trial registration explicitly 12 (71%) 7 (13%) 19 (26%)
Trial registration implicitly 0 (0%) 29 (52%) 29 (40%)
Protocol adherence/amendment 
explicitly
12 (71%) 20 (36%) 32 (44%)
Protocol adherence/amendment 
implicitly
2 (12%) 24 (43%) 26 (36%)
Trial publication explicitly 14 (82%) 35 (63%) 49 (67%)
Trial publication implicitly 1 (6%) 13 (23%) 14 (19%)
Monitoring against guidelines explicitly 11 (65%) 36 (64%) 47 (64%)
Monitoring against guidelines implicitly 1 (6%) 11 (20%) 12 (16%)
Publication of negative studies explicitly 6 (35%) 5 (9%) 11 (15%)
Publication of negative studies implicitly 3 (18%) 24 (43%) 27 (37%)
Publication of negative outcomes 
explicitly
6 (35%) 5 (9%) 11 (15%)
Publication of negative outcomes 
implicitly
3 (18%) 24 (43%) 27 (37%)
1. Each charity/organisation may refer to one or more other guidelines
Limited contact meant that there was initial contact with the organisation/charity to confirm that they did fund clinical trials and the maximum grant 
available was, but then no further information was forthcoming.
Institution means the guidelines refer to the guidelines issued by the university or other institution were the trial is to be conducted from.
Charity specific means that the charity has specific guidelines for the particular disease/illness but not necessarily good research practice guidelines.
National regulations and guidelines are any other guidelines issued nationally e.g. for the UK, America e.t.c.
Legal guidelines means the guidelines refer to specific legal guidelines for clinical trials or the specific disease/illness being studied.
Table 1: Summary of response from organisations and charities (Continued)Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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Table 2: Statements specific to outcomes, ORB or publication bias
Organisation/Charity Statements specific to outcomes, ORB or publication bias
Chief Scientist Office of the Scottish Executive Health Department There should be free access to information both on research being 
conducted and on the findings of the research – positive or negative-
once these have been subjected to appropriate scientific review. When 
established, findings (including negative findings) are published in ways 
that allow critical review and dissemination to those who could benefit 
from them.
Department of Health (England) When established, findings (including negative findings) are published in 
ways that allow critical review and dissemination to those who could 
benefit from them.
World Health Organisation Procedures for communicating deviation from the original statistical plan 
(any deviation from the original statistical plan should be described and 
justified in the protocol and/or in the final report).
The study protocol may include; in the case of a negative outcome, an 
assurance that the results will be made available, as appropriate, through 
publication or by reporting to the drug registration authority.
Both authors and publishers have ethical obligations. In publication of 
the results of research, the investigators are obliged to preserve the 
accuracy of the results. Negative as well as positive results should be 
published or otherwise publicly available. Sources of funding, 
institutional affiliations and any possible conflicts of interest should be 
declared in the publication. Reports of experimentation not in 
accordance with the principles laid down in this Declaration should not 
be accepted for publication.
Medical Research Council (UK) The analysis should follow a carefully written analysis plan. All outcome 
measures stated in the protocol should be fully analysed.
It is equally unethical not to report results, or to exaggerate the 
importance of results for medical practice or policy.
Trials should be submitted to a peer reviewed journal irrespective of the 
results of the trial.
The council's mission to improve quality of life also carries with it the 
imperative to report results that are directly relevant; there can be no 
freedom not to do so. This is also required as one of the conditions of 
gaining ethical approval for studies using human participants. It is 
increasingly recognised that that many results of clinical studies are not 
published but are nevertheless significant in building up an overall picture 
of the efficacy of a particular diagnostic, therapeutic or preventive 
approach.
The National Health and Medical Research Council (Australia) Procedures for reporting any deviation(s) from the original statistical 
plan (any deviation(s) from the original statistical plan should be 
described and justified in the protocol and/or in the final report, as 
appropriate).
Disseminating and communicating results, whether favourable or 
unfavourable, in ways that permit scrutiny and contribute to public 
knowledge and understanding.
The National Institute for Allergies and Infectious Diseases (USA) Outcome measures should be prioritized. Generally, there should be 
just one primary variable, with evidence that it will provide a clinically 
relevant, valid and reliable measure of the primary objective.
Health and Social Care Research and Development Office 
(Northern Ireland)
When established, findings (including negative findings) are published in 
ways that allow critical review and dissemination to those who could 
benefit from them. Other researchers have access to the data on which 
the findings are based.
Ataxia UK Ataxia UK recognises that journals normally publish only positive 
findings, and that negative findings may nevertheless be of value. Ataxia 
UK therefore reserves the right to publish summaries of negative as well 
as positive findings on its website or elsewhere.Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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be reported and fully justified in the final report. NIAID
state that there should generally only be one primary out-
come and that this should be clearly defined in the proto-
col.
Tables 3 (see Additional file 2) and 4 (see Additional file
3) include details of information found in the guidelines
or through response to questionnaires for organisations
and charities respectively.
Discussion
This review provides a narrative summary of the guide-
lines that are available from major organisations across
the world and UK charities that fund RCTs. We found that
funders of clinical trials have not yet incorporated recent
concerns about ORB into their recommendations for
researchers. There is a need to provide detailed guidance
for those conducting and reporting clinical trials to help
prevent the selective reporting of outcomes.
In this review we focussed on guidelines for good research
practice for clinical trials. The main limitation of this
review is that the search of organisations was not exhaus-
tive. We concentrated mainly on organisations from
Europe, USA, Australia and South Africa, and only UK
charities have been investigated. However, the ICH guide-
lines, discussed below, are international.
The majority of guidelines provided no references to the
problem for several of the questions in the questionnaire
(see Additional file 1, Appendix 3); these were mainly
questions specifically regarding outcomes. This is likely to
be due to the fact that awareness of the problem of ORB
has been limited over the past decade. As we have found,
the importance of this issue has not filtered through to
these guidelines.
Many of the guidelines state that a trial should be regis-
tered before it begins. The purpose of registration is to
inform other researchers of trials that are being con-
ducted; the aims include reducing publication bias and
the duplication of research [6].
Several guidelines that we obtained discuss the impor-
tance of adherence to the protocol and state that amend-
ments to the protocol should be reported. This issue is
related to ORB as outcomes that are specified as primary
or secondary in the protocol should be written up as such
in the final report. Insertion of new outcomes and dele-
tion of old outcomes should not occur unless an official
amendment to the protocol was made, and such changes
should be reported in journal articles. The ICH E3 [25]
guideline states that "if the protocol did not identify the
primary variables, the study report should explain how
these critical variables were selected (e.g., by reference to
publications, guidelines or previous actions by regulatory
authorities) and when they were identified (i.e., before or
after the study was completed and unblinded)." The Med-
icines and Healthcare products Regulatory Agency
(MHRA) state that "new questions based on the observed
data may well emerge during the analysis. This additional
work should be strictly distinguished in the report from
the work which was planned in the protocol." No such
reports were found in the cohort of 102 trials studied by
Chan et al [11] despite over half having changed their pri-
mary outcomes in some way.
Chronic Granulomatous Disorder Research Trust The Institution will ensure that publication of findings in peer reviewed 
journals is sought as soon as possible during, and after conclusion, of the 
Project even where results prove negative.
Cystic Fibrosis Trust Grantholders are expected to seek publication of findings in peer 
reviewed journals as soon as possible during, and after conclusion, of the 
project even where results prove negative.
Multiple Sclerosis Society of Great Britain and Northern Ireland The Multiple Sclerosis Society requires its researchers to disseminate 
the results of the research that it funds in the usual manner, for example 
by publication in peer reviewed journals and presentation at meetings, as 
soon as possible during, and after conclusion, of the project even where 
results prove negative or inconclusive.
Researchers should be honest in respect of their own actions in 
research and in their responses to the actions of other researchers. This 
applies to the whole range of research work, including experimental 
design, generating and analysing data, applying for funding, publishing 
results, and acknowledging the direct and indirect contribution of 
colleagues, collaborators and others.
Research into ageing Unless otherwise stated in the Offer Letter, Grantholders are required 
by the Charity to seek publication of findings in peer reviewed journals 
(as appropriate) as soon as possible during, and after conclusion, of the 
Project even where results prove negative.
Table 2: Statements specific to outcomes, ORB or publication bias (Continued)Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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Publication is often mentioned in funders' guidelines,
stating that work should be published in a peer reviewed
journal or at least stating that it should be disseminated.
The Association of the British Pharmaceutical Industry
states that work should be published and refers to guide-
lines on good publication practice [26], which aim to
ensure that clinical trials sponsored by pharmaceutical
companies are published in a responsible and ethical
manner.
Many RCTs are carefully monitored by trial steering com-
mittees and this requirement is stated in several of the
guidelines/terms and conditions. Monitoring tends to
focus on whether trialists are following correct proce-
dures. Therefore, issues such as protocol adherence and
trial registration should be noticed and highlighted if they
are not done correctly. Once a trial has been completed,
such oversight may diminish. Ensuring that trial results
are published may also be a concern of the data monitor-
ing committee [23].
These four issues – registration of a trial, protocol adher-
ence/amendment, publication and monitoring against
guidelines – are important with regard to ORB, as the
more rigorous the guidelines are in these areas, adherence
makes ORB less likely.
Statements found in the guidelines generally refer to pub-
lication of negative and positive findings which could be
interpreted as referring to study publication bias (i.e. non-
publication of whole studies) or ORB (selective non-pub-
lication of outcomes). The empirical evidence of publica-
tion bias was first seen in the early 1990's [2] and much
work has now been done in the area of publication bias
since [6]. By contrast, studies providing the empirical evi-
dence for ORB were published more recently between
2002 and 2008 [2]. Some of the more detailed and most
often referred to guidelines, such as ICH [17,27,25,28]
and MRC Good Research Practice guidelines [29], were
written before 2000, when ORB first began to be recog-
nised [7]. However, the Department of Health's Research
Governance Framework [30] was updated in 2005 and
provides no guidelines aimed specifically at preventing
ORB.
Organisations tended to have their own guidelines
whereas the charities mostly had terms and conditions
but referred to some of the organisations' guidelines. This
may reflect some of the charities being small and that
some had only recently begun to fund RCTs.
The CONSORT Statement [20] addresses the write up of
the final report and does not link this explicitly to the trial
protocol. It does not specifically refer to ORB as it only
states that outcome measures should be specified in the
methods section and fully reported in the results section.
Although this recommendation attempts to prevent par-
tial reporting of outcomes (e.g. p-value only), and in addi-
tion may help identify outcomes that have not been
reported, these recommendations alone will not prevent
the selective reporting of outcomes. The CONSORT state-
ment does not state that all outcomes that were included
in the protocol should be stated in the methods section
and reported in the results section of the final report. It
also does not state that outcomes should not be upgraded
or downgraded between the protocol and final report, or
that new outcomes should not be added or old outcomes
deleted based on their results. Therefore even when trial-
ists follow the CONSORT Statement, it would be impossi-
ble to determine whether all outcomes in the protocol are
reported in the final report. However, these concerns will
be addressed in the revision of CONSORT that is under
way. (DG Altman, personal communication)
Since this work has been completed, the members of the
WHO Registry Platform Working Group on the Reporting
of Findings of Clinical Trials have proposed that "the find-
ings of all clinical trials must be made publicly available
[31]."
In the USA legislation is in place so that legally researchers
are required to make their findings publicly available
within a specific timeframe [32]. The legislation states that
"The expansion of the registry data bank to include results
of clinical trials; beginning not later than 90 days after the
date of the enactment of the Food and Drug Administra-
tion Amendments Act of 2007, for those clinical trials that
form the primary basis of an efficacy claim or are con-
ducted after the drug involved is approved or after the
device involved is cleared or approved, the Secretary shall
ensure that the registry data bank includes links to results
information." It also includes specifics on the reporting of
outcomes: "The primary and secondary outcome meas-
ures as submitted and a table of values for each of the pri-
mary and secondary outcome measures for each arm of
the clinical trial, including the results of scientifically
appropriate tests of the statistical significance of such out-
come measures." It is hoped that these initiatives will
reduce the problem of ORB.
This review forms part of the Outcome Reporting Bias in
Trials (ORBIT) project [33]. It has been funded to inves-
tigate how prevalent outcome reporting bias is in trials
within systematic reviews and whether this has a large
impact on the conclusions of the reviews, as well as trying
to understand why trialists do not report all outcomes and
investigating the prevalence of ORB in individual patient
data reviews on the Cochrane Collaboration Individual
Patient Data Methods Working Group register. The iden-Trials 2008, 9:66 http://www.trialsjournal.com/content/9/1/66
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tification of this gap in the guidelines is part of a suite of
initiatives to reduce the problem of ORB.
Conclusion
Our review indicates that there is a need to provide more
detailed guidance for those conducting and reporting clin-
ical trials to help prevent the selective reporting of out-
comes. Current guidelines need to be updated, as many
include statements regarding the publication of 'negative'
studies to prevent publication bias but do not go as far as
mentioning ORB. In the MRC guidelines the statement 'all
outcomes stated in the protocol should be fully analysed'
needs to be extended to specify that prespecified primary
and secondary outcomes should be fully reported and
that outcomes should not be selected for inclusion in the
final report based on their results. Recommendations for
text to include in research funders' guidelines are sug-
gested (see Additional file 4).
The next step is to conduct a systematic review of empiri-
cal studies that have compared protocols to publications,
to assess their adherence to specified guidelines. It would
then be important to conduct a survey of trialists to see
which guidelines they follow and their adherence to
them, to assess their understanding of the issues discussed
in this paper.
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